Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
Status:
Completed
Trial end date:
2019-11-14
Target enrollment:
Participant gender:
Summary
This study was conducted because the FDA requested clinical information on potential effects
of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal
endothelium from a 1-year (minimum) post-approval clinical study to support that there are no
adverse effects on the corneal endothelium following intravitreal injections of Macugen.
Phase:
Phase 4
Details
Lead Sponsor:
Bausch & Lomb Incorporated Valeant Pharmaceuticals International, Inc.